Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Videos

Showing 47 results.

ABCL - 026 Video-1

A Manifold-Based Topological Approach for Identifying Stage-Divergent Apoptotic Signatures in DLBCL

Alamin Mustafa

ABCL - 216 Video-1

Effect of HIV Infection on Treatment Outcomes in Patients With Diffuse Large B-Cell Lymphoma

Anastasia Galitsyna

ABCL - 484 Video-1

A Real-World Study of the Effectiveness and Safety of Post-Tafasitamab Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Kim Saverno

ABCL - 489 Video-1

Primary Outcomes from the Phase 3 Study of Tafasitamab (Tafa) Plus Lenalidomide (Len) and R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (frontMIND)

Jason Westin

ABCL - 615 Video-1

EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Christina Y Lee

ABCL - 736 Video-1

Outpatient Treatment With Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety Results From a Phase 2 Study

John M. Burke

ABCL - 853 Video-1

Vispa-cel, an Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Phase 1 Clinical Trial)

Mohamad Cherry

ALL - 1125 Video-1

Improving Efficacy and Safety Outcomes in Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Morphologic Remission Treated With Obecabtagene Autoleucel

Elias Jabbour

ALL - 280 Video-1

Topological Simplification and Loss of Regulatory Complexity in the DNA Repair Pathway of Acute Lymphoblastic Leukemia

Alamin Mustafa

ALL - 576 Video-1

Systematic Literature Review and Network Meta-Analyses of Hypersensitivity in Patients Receiving Asparaginase Treatment

Luke Maese

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.